GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: IL17-MS3086 | IL17MS3086 | M-1095 | M1095 | MSB-0010841 | MSB0010841 | SEQ ID 836 [WO2012156219A1]
Compound class:
Antibody
Comment: Sonelokimab (MSB0010841; M1095) is an anti-IL-17A/F single chain camelid nanobody [1]. The peptide sequence for proposed INN sonelokimab is a 100% match for SEQ ID 836 that is claimed in Merck/Ablynx patent WO2012156219A1. Sonelokimab potently binds to both IL-17A and -F and prevents IL-17R pathway activation (e.g . IL-6 production), and was designed for anti-inflammatory potential.
|
Classification ![]() |
|
| Compound class | Antibody |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 11137 | sonelokimab |
Synonyms ![]() |
| IL17-MS3086 | IL17MS3086 | M-1095 | M1095 | MSB-0010841 | MSB0010841 | SEQ ID 836 [WO2012156219A1] |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 971 |
| Other databases | |
| GtoPdb PubChem SID | 385612250 |
| Search PubMed clinical trials | sonelokimab |
| Search PubMed titles | sonelokimab |
| Search PubMed titles/abstracts | sonelokimab |